Evidence map›Paper›PMID 31742123›Full record

ArticleJournal of family medicine and primary care2019

Camel milk for reduction of diabetes risk: Are we heading toward the right direction?

Komal Shah, Sandul Yasobant, Deepak Saxena

Abstract read
In one paragraph

Article in Journal of family medicine and primary care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Komal ShahIndian Institute of Public Health - Gandhinagar, Gujarat, India.
Sandul YasobantCenter for Development Research (ZEF), University of Bonn, Germany.
Deepak SaxenaIndian Institute of Public Health - Gandhinagar, Gujarat, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetes is emerging as an important public health problem in India imparting huge burden on healthcare economics. Recently a milk packaging company has introduced camel milk product with its potential use in reducing risk of diabetes. In this study, we had evaluated the available evidences and found that though camel milk may have some benefits for the patients with type 1 diabetes, its efficacy for improving glycemic profile of type 2 diabetes is highly controversial and further evidences in the form of randomized controlled trials are needed to substantiate the effect.

Indexed as

Camel milkIndiatype 1 diabetestype 2 diabetes

Identifiers

PMID31742123
PMCPMC6857414

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.